Department of Respiratory and Critical Care, West China School of Medicine and West China Hospital, Sichuan University, 610041, China.
Department of Critical Care Medicine, West China School of Medicine and West China Hospital, Sichuan University, 610041, China.
Am J Emerg Med. 2018 Feb;36(2):226-233. doi: 10.1016/j.ajem.2017.07.083. Epub 2017 Jul 28.
The effects of high flow nasal cannula (HFNC) on adult patients when used before mechanical ventilation (MV) are unclear. We aimed to determine the effectiveness of HFNC when used before MV by comparison to conventional oxygen therapy (COT) and noninvasive positive pressure ventilation (NIPPV).
The Pubmed, Embase, Medline, Cochrane Central Register of Controlled Trials (CENTRAL) as well as the Information Sciences Institute (ISI) Web of Science were searched for all the controlled studies that compared HFNC with NIPPV and COT when used before MV in adult patients. The primary outcome was the rate of endotracheal intubation and the secondary outcomes were intensive care unit (ICU) mortality and length of ICU stay (ICU LOS).
Eight trials with a total of 1084 patients were pooled in our final studies. No significant heterogeneity was found in outcome measures. Compared both with COT and NIPPV, HFNC could reduce both of the rate of endotracheal intubation (OR 0.62, 95% CI 0.38-0.99, P=0.05; OR 0.48, 95% CI 0.31-0.73, P=0.0006) and ICU mortality (OR 0.47, 95% CI 0.24-0.93, P=0.03; OR 0.36, 95% CI 0.20-0.63, P=0.0004). As for the ICU LOS, we did not find any advantage of HFNC over COT or NIPPV.
When used before MV, HFNC can improve the prognosis of patients compared both with the COT and NIPPV.
高流量鼻导管(HFNC)在成人患者机械通气(MV)前使用的效果尚不清楚。我们旨在通过与常规氧疗(COT)和无创正压通气(NIPPV)比较,确定 HFNC 在 MV 前使用的效果。
检索 Pubmed、Embase、Medline、Cochrane 对照试验中心注册库(CENTRAL)和信息科学研究所(ISI)Web of Science,以查找所有比较 HFNC 与 NIPPV 和 COT 在成人患者 MV 前使用的对照研究。主要结局是气管插管率,次要结局是重症监护病房(ICU)死亡率和 ICU 住院时间(ICU LOS)。
纳入的 8 项试验共 1084 例患者,最终研究中进行了汇总。在结局测量中没有发现显著的异质性。与 COT 和 NIPPV 相比,HFNC 均能降低气管插管率(OR 0.62,95%CI 0.38-0.99,P=0.05;OR 0.48,95%CI 0.31-0.73,P=0.0006)和 ICU 死亡率(OR 0.47,95%CI 0.24-0.93,P=0.03;OR 0.36,95%CI 0.20-0.63,P=0.0004)。对于 ICU LOS,HFNC 并没有优于 COT 或 NIPPV。
HFNC 在 MV 前使用可改善患者预后,与 COT 和 NIPPV 相比具有优势。